Summary
Abbott Laboratories reported strong performance in its 2022 fiscal year, driven by its diversified healthcare portfolio across Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutritional Products. The company demonstrated resilience despite various market challenges, including supply chain disruptions and the ongoing impact of the COVID-19 pandemic, though the latter led to a notable decline in COVID-19 testing revenues as anticipated. Key growth drivers included the Medical Devices segment, bolstered by its Diabetes Care products like FreeStyle Libre, and the Established Pharmaceuticals segment, which saw continued expansion in emerging markets. The company navigated the significant impact of a voluntary infant formula recall and subsequent manufacturing issues within its Nutritional Products segment, implementing strategies to mitigate supply shortages. Despite these challenges, Abbott maintained a strong financial position, evidenced by consistent dividend payouts and a significant share repurchase program. The company also announced a strategic acquisition in the medical device space, signaling continued investment in growth and innovation. Management expressed confidence in future growth driven by product development and market expansion across all segments.
Financial Highlights
52 data points| Revenue | $43.65B |
| Cost of Revenue | $19.14B |
| Gross Profit | $24.51B |
| R&D Expenses | $2.89B |
| SG&A Expenses | $11.25B |
| Operating Expenses | $35.29B |
| Operating Income | $8.36B |
| Interest Expense | $558.00M |
| Net Income | $6.93B |
| EPS (Basic) | $3.94 |
| EPS (Diluted) | $3.91 |
| Shares Outstanding (Basic) | 1.75B |
| Shares Outstanding (Diluted) | 1.76B |
Key Highlights
- 1Abbott Laboratories' net sales were $43.7 billion for the year ended December 31, 2022.
- 2The company's business is diversified across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
- 3Medical Devices segment sales grew 8.1% (excluding foreign exchange) in 2022, driven by Diabetes Care, Structural Heart, Electrophysiology, and Heart Failure.
- 4Diagnostic Products segment sales increased 10.4% (excluding foreign exchange) in 2022, primarily due to demand for COVID-19 diagnostic tests, though this is expected to decline in 2023.
- 5Nutritional Products segment sales decreased 6.2% (excluding foreign exchange) in 2022, largely impacted by a voluntary infant formula recall and manufacturing stoppage in the US.
- 6Established Pharmaceutical Products segment sales increased 10.6% (excluding foreign exchange) in 2022, driven by growth in emerging markets like India, China, and Brazil.
- 7Abbott announced a definitive agreement to acquire Cardiovascular Systems, Inc. (CSI) for approximately $890 million to expand its vascular device offerings.